Characterization and differential expression of a newly identified phosphorylated isoform of the human 20S proteasome β7 subunit in tumor vs. normal cell lines

Fundamental and Clinical Pharmacology

Volumn 23, Issue 2, 2009, Pages 215-224

  Eang, Rothmony ^a   Girbal Neuhauser, Elisabeth ^b   Xu, Bo ^c   Gairin, Jean Edouard ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Université Paul Sabatier   (France)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

7 subunit; Catalytic activities; Human 20S proteasome; Phosphorylated isoform; Tumor cell lines

Indexed keywords

20S PROTEASOME BETA SUBUNIT; PROTEASOME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ENZYME PURIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; CELL LINE; CELL LINE, TUMOR; CHYMOTRYPSIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; PEPTIDES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ISOFORMS; TRYPSIN;

EID: 62849098196     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00665.x     Document Type: Article

References (50)

1. Elliott P.J., Ross J.S. The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. (2001) 116 637 646.
2. Goldberg A.L., Rock K. Not just research tools - proteasome inhibitors offer therapeutic promise. Nat. Med. (2002) 8 338 340.
3. Zhang H.G., Wang J., Yang X., Hsu H.C., Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene (2004) 23 2009 2015.
4. Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry (1990) 29 10289 10297.
5. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer (2004) 4 349 360.
6. Suh K.S., Goy A. Bortezomib in mantle cell lymphoma. Future Oncol. (2008) 4 149 168.
7. Richardson P.G., Mitsiades C., Hideshima T., Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. (2006) 57 33 47.
8. Johnson L. Protein kinases and their therapeutic exploitation. Biochem. Soc. Trans. (2007) 35 7 11.
9. Bardelli A., Saha S., Sager J.A. et al. PRL-3 expression in metastatic cancers. Clin. Cancer Res. (2003) 9 5607 5615.
10. Wu X., Zeng H., Zhang X. et al. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am. J. Pathol. (2004) 164 2039 2054.
11. Polato F., Codegoni A., Fruscio R. et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin. Cancer Res. (2005) 11 6835 6839.
12. Tsimokha A.S., Mittenberg A.G., Kulichkova V.A., Kozhukharova I.V., Gause L.N., Konstantinova I.M. Changes in composition and activities of 26S proteasomes under the action of doxorubicin - apoptosis inductor of erythroleukemic K562 cells. Cell Biol. Int. (2007) 31 338 348.
13. Li N., Lerea K.M., Etlinger J.D. Phosphorylation of the proteasome activator PA28 is required for proteasome activation. Biochem. Biophys. Res. Commun. (1996) 225 855 860.
14. Castano J.G., Mahillo E., Arizti P., Arribas J. Phosphorylation of C8 and C9 subunits of the multicatalytic proteinase by casein kinase II and identification of the C8 phosphorylation sites by direct mutagenesis. Biochemistry (1996) 35 3782 3789.
15. Mason G.G., Murray R.Z., Pappin D., Rivett A.J. Phosphorylation of ATPase subunits of the 26S proteasome. FEBS Lett. (1998) 430 269 274.
16. Satoh K., Sasajima H., Nyoumura K.I., Yokosawa H., Sawada H. Assembly of the 26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit. Biochemistry (2001) 40 314 319.
17. Feng Y., Longo D.L., Ferris D.K. Polo-like kinase interacts with proteasomes and regulates their activity. Cell Growth Differ. (2001) 12 29 37.
18. Claverol S., Burlet-Schiltz O., Girbal-Neuhauser E., Gairin J.E., Monsarrat B. Mapping and structural dissection of human 20S proteasome using proteomic approaches. Mol. Cell Proteomics (2002) 1 567 578.
19. Bardag-Gorce F., Venkatesh R., Li J., French B.A., French S.W. Hyperphosphorylation of rat liver proteasome subunits: the effects of ethanol and okadaic acid are compared. Life Sci. (2004) 75 585 597.
20. Horiguchi R., Yoshikuni M., Tokumoto M., Nagahama Y., Tokumoto T. Identification of a protein kinase which phosphorylates a subunit of the 26S proteasome and changes in its activity during meiotic cell cycle in goldfish oocytes. Cell. Signal. (2005) 17 205 215.
21. Kopp F., Hendil K.B., Dahlmann B., Kristensen P., Sobek A., Uerkvitz W. Subunit arrangement in the human 20S proteasome. Proc. Natl. Acad. Sci. U S A (1997) 94 2939 2944.
22. Groll M., Ditzel L., Lowe J. et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature (1997) 386 463 471.
23. Unno M., Mizushima T., Morimoto Y. et al. The structure of the mammalian 20S proteasome at 2.75 Å resolution. Structure (2002) 10 609 618.
24. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 268 726 731.
25. Tanaka K., Tamura T., Yoshimura T., Ichihara A. Proteasomes: protein and gene structures. New Biol. (1992) 4 173 187.
26. Heinemeyer W., Fischer M., Krimmer T., Stachon U., Wolf D.H. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J. Biol. Chem. (1997) 272 25200 25209.
27. Mason G.G., Hendil K.B., Rivett A.J. Phosphorylation of proteasomes in mammalian cells. Identification of two phosphorylated subunits and the effect of phosphorylation on activity. Eur. J. Biochem. (1996) 238 453 462.
28. Bose S., Stratford F.L., Broadfoot K.I., Mason G.G., Rivett A.J. Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon. Biochem. J. (2004) 378 177 184.
29. Ludemann R., Lerea K.M., Etlinger J.D. Copurification of casein kinase II with 20S proteasomes and phosphorylation of a 30-kDa proteasome subunit. J. Biol. Chem. (1993) 268 17413 17417.
30. Fernandez Murray P., Pardo P.S., Zelada A.M., Passeron S. In vivo and in vitro phosphorylation of Candida albicans 20S proteasome. Arch. Biochem. Biophys. (2002) 404 116 125.
31. Bose S., Brooks P., Mason G.G., Rivett A.J. gamma-Interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation. Biochem. J. (2001) 353 291 297.
32. Benedict C.M., Ren L., Clawson G.A. Nuclear multicatalytic proteinase alpha subunit RRC3: differential size, tyrosine phosphorylation, and susceptibility to antisense oligonucleotide treatment. Biochemistry (1995) 34 9587 9598.
33. Xu B., Monsarrat B., Gairin J.E., Girbal-Neuhauser E. Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells. Fundam. Clin. Pharmacol. (2004) 18 171 180.
34. Xu B. Le protéasome 20S humain, une nouvelle cible en thérapie anticancéreuse: effet de l'ajoene, molécule naturelle anti-tumorale, et impact de modifications post-traductionnelles sur son activité catalytique. PhD Thesis, Université Paul Sabatier, Toulouse, France, 2003.
35. Vispe S., Vandenberghe I., Robin M. et al. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem. Pharmacol. (2007) 73 1863 1872.
36. Seet B.T., Dikic I., Zhou M.M., Pawson T. Reading protein modifications with interaction domains. Nat. Rev. Mol. Cell Biol. (2006) 7 473 483.
37. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. (2002) 82 373 428.
38. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. (1998) 17 7151 7160.
39. Rivett A.J., Bose S., Brooks P., Broadfoot K.I. Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie (2001) 83 363 366.
40. Meri S., Baumann M. Proteomics: posttranslational modifications, immune responses and current analytical tools. Biomol. Eng. (2001) 18 213 220.
41. Larsen M.R., Thingholm T.E., Jensen O.N., Roepstorff P., Jorgensen T.J. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell Proteomics (2005) 4 873 886.
42. Shchemelinin I., Sefc L., Necas E. Protein kinases, their function and implication in cancer and other diseases. Folia Biol. (Praha) (2006) 52 81 100.
43. Duncan J.S., Litchfield D.W. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim. Biophys. Acta (2008) 1784 33 47.
44. Jayarapu K., Griffin T.A. Protein-protein interactions among human 20S proteasome subunits and proteassemblin. Biochem. Biophys. Res. Commun. (2004) 314 523 528.
45. Iwafune Y., Kawasaki H., Hirano H. Electrophoretic analysis of phosphorylation of the yeast 20S proteasome. Electrophoresis (2002) 23 329 338.
46. Zhang F., Hu Y., Huang P., Toleman C.A., Paterson A.J., Kudlow J.E. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem. (2007) 282 22460 22471.
47. Wilkinson K.D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell Dev. Biol. (2000) 11 141 148.
48. Wang J., Maldonado M.A. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell. Mol. Immunol. (2006) 3 255 261.
49. Miskad U.A., Semba S., Kato H. et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch. (2007) 450 303 310.
50. Daouti S., Li W.H., Qian H. et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. (2008) 68 1162 1169.